Skip to content

Bausch Health Companies BHC Bausch + Lomb — Goodwill, impairment loss

Other segment segments

Salix
$1.43B
Diversified
$0-100%
International
$0
Solta Medical
$0

Similar metrics at other companies

Ashland logo
ASHLife Sciences — Goodwill Impaired Accumulated Impairment Loss
$375M
Danaher logo
DHRLife Sciences — Goodwill Impairment
$0
CarGurus, Inc. logo
CARGImpairment Goodwill
$4.9M-83.0%
Gentex logo
GNTXOther — Goodwill, Impairment Loss
$0-100%
Pool Corporation logo
POOLReportable — Goodwill Impairment
$71.25K
Coty logo
COTYConsumer Beauty — Goodwill, Impaired, Accumulated Impairment Loss
$1.17B+25.5%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's bausch + lomb — goodwill, impairment loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's bausch + lomb — goodwill, impairment loss?
Bausch Health Companies (BHC) reported bausch + lomb — goodwill, impairment loss of $0 in Q1 2026.
What does bausch + lomb — goodwill, impairment loss mean?
Measures the reduction in the carrying value of goodwill when the implied fair value of the Bausch + Lomb reporting unit falls below its book value. This is a critical indicator of potential overpayment for past acquisitions or a decline in the segment's long-term earnings potential.